轴性脊椎关节炎的疾病修饰 - 仍然是一个争议?
Manouk de Hooge1, Désirée van der Heijde2
1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.
Current opinion in rheumatology
|May 7, 2024
概括
对轴性脊椎关节炎 (axSpA) 的疾病修饰疗法显示出混合的结果. 虽然一些治疗方法可以减少炎症,但它们对长期结构进展的影响仍然不确定,需要进一步研究.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 轴性脊柱关节炎 (axSpA) 是一种影响脊柱的慢性炎症状况.
- 有效的疾病修饰疗法对于管理axSpA和预防结构损伤至关重要.
研究的目的:
- 审查 axSp.A. 的疾病修饰疗法的最新进展.
- 评估各种治疗方法在阻止结构进展方面的有效性.
主要方法:
- 关于NSAIDs,TNF抑制剂 (TNFi),IL-17抑制剂 (IL-17i) 和JAK抑制剂对axSpA.A.的最新研究的综述.
- 关于对炎症和结构进展的影响的证据分析 (X射线和MRI).
主要成果:
- 关于当前疗法阻碍结构性进展的能力存在相互矛盾的证据.
- 一些研究表明,抑制炎症是有前途的,但长期结构效应尚不确定.
- 对IL-17i和TNFi进行比较的试验在脊髓进展方面没有显著差异;NSAID对进展的影响仍在争论中.
结论:
- 目前axSpA疗法在预防结构性进展方面的有效性需要进一步研究.
- 未来的研究应该专注于强大的试验和新的成像工具来评估疾病的修饰.
- 了解人口和治疗趋势对于优化axSpA管理至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Antiasthma Drugs: Leukotriene Modifiers
281
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
281
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Drugs for Treatment of Ulcerative Colitis in IBD
136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136
Genome-wide Association Studies-GWAS
13.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.3K


